News
Public · Published
Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera
Idorsia started FAB-KLEAR, a pivotal Phase 3 kidney biopsy study of lucerastat in adults with Fabry disease, and signed a co-development and commercialization agreement with Nxera. After exercising its option, Nxera will pay Idorsia CHF 7 million and help fund the global Phase 3 program.
Published:
Updated:
What happened
Idorsia started FAB-KLEAR, a pivotal Phase 3 kidney biopsy study of lucerastat in adults with Fabry disease, and signed a co-development and commercialization agreement with Nxera. After exercising its option, Nxera will pay Idorsia CHF 7 million and help fund the global Phase 3 program.
Confirmed
Global impact / market context
The CHF 7 million payment and Nxera's shared funding reduce what Idorsia must spend alone on late-stage testing, which means less strain on cash available. Nxera gains rights in Japan and selected Asia Pacific markets, so Idorsia keeps royalties on sales there.
Analyst inference
For biotech investors, a partner paying to join a Phase 3 program signals outside confidence in the treatment's chances. For Nxera, the deal adds a late-stage kidney therapy candidate to its pipeline and ties future revenue to trial success and regulatory approval in its territories.
Analyst inference
What to watch
- Watch whether FAB-KLEAR, the kidney biopsy study, enrolls adult Fabry disease patients on schedule and whether its results support a regulatory filing for lucerastat. Confirmed
- Watch whether Nxera pays the CHF 7 million and contributes its share of Phase 3 costs as agreed, since that cash supports Idorsia's development spending. Proposed
- Watch royalties on net sales in Japan and selected Asia Pacific territories, which tie Idorsia's future revenue to Nxera's commercialization success rather than upfront cash alone. Analyst inference